Supernus Pharmaceuticals, Inc. (0LB2.L)
USD 31.44
(-2.48%)
USD 31.44
(-2.48%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 77.4 Million USD | -15.44% |
| 2022 | 91.54 Million USD | 6.49% |
| 2021 | 85.95 Million USD | 77.88% |
| 2020 | 48.32 Million USD | 81.48% |
| 2019 | 26.62 Million USD | 3.78% |
| 2018 | 25.65 Million USD | 57.38% |
| 2017 | 16.3 Million USD | -2.96% |
| 2016 | 16.8 Million USD | 33.48% |
| 2015 | 12.58 Million USD | -6.35% |
| 2014 | 13.44 Million USD | 87.93% |
| 2013 | 7.15 Million USD | 520.83% |
| 2012 | 1.15 Million USD | 196.14% |
| 2011 | 389 Thousand USD | -94.24% |
| 2010 | 6.75 Million USD | 187.81% |
| 2009 | 2.34 Million USD | -64.16% |
| 2008 | 6.54 Million USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 68.15 Million USD | -9.22% |
| 2024 Q3 | 63.98 Million USD | -6.12% |
| 2024 Q1 | 75.07 Million USD | -3.01% |
| 2023 Q2 | 90.56 Million USD | -0.64% |
| 2023 Q1 | 91.14 Million USD | -0.43% |
| 2023 Q4 | 77.4 Million USD | -7.27% |
| 2023 FY | 77.4 Million USD | -15.44% |
| 2023 Q3 | 83.48 Million USD | -7.82% |
| 2022 Q4 | 91.54 Million USD | 10.07% |
| 2022 FY | 91.54 Million USD | 6.49% |
| 2022 Q1 | 88.79 Million USD | 3.3% |
| 2022 Q2 | 84.86 Million USD | -4.43% |
| 2022 Q3 | 83.16 Million USD | -2.0% |
| 2021 Q2 | 58.39 Million USD | 16.26% |
| 2021 Q4 | 85.95 Million USD | 42.9% |
| 2021 Q1 | 50.22 Million USD | 3.93% |
| 2021 FY | 85.95 Million USD | 77.88% |
| 2021 Q3 | 60.15 Million USD | 3.02% |
| 2020 Q3 | 42.46 Million USD | 20.17% |
| 2020 Q1 | 24.41 Million USD | -8.3% |
| 2020 Q2 | 35.33 Million USD | 44.72% |
| 2020 FY | 48.32 Million USD | 81.48% |
| 2020 Q4 | 48.32 Million USD | 13.8% |
| 2019 Q4 | 26.62 Million USD | 4.41% |
| 2019 FY | 26.62 Million USD | 3.78% |
| 2019 Q1 | 26.51 Million USD | 3.35% |
| 2019 Q2 | 26.02 Million USD | -1.86% |
| 2019 Q3 | 25.5 Million USD | -2.0% |
| 2018 Q1 | 19.07 Million USD | 17.0% |
| 2018 Q4 | 25.65 Million USD | 10.22% |
| 2018 FY | 25.65 Million USD | 57.38% |
| 2018 Q3 | 23.28 Million USD | 12.57% |
| 2018 Q2 | 20.68 Million USD | 8.41% |
| 2017 Q3 | 14.94 Million USD | -10.08% |
| 2017 FY | 16.3 Million USD | -2.96% |
| 2017 Q1 | 19.16 Million USD | 14.08% |
| 2017 Q2 | 16.62 Million USD | -13.27% |
| 2017 Q4 | 16.3 Million USD | 9.08% |
| 2016 FY | 16.8 Million USD | 33.48% |
| 2016 Q4 | 16.8 Million USD | -3.74% |
| 2016 Q3 | 17.45 Million USD | 6.6% |
| 2016 Q2 | 16.37 Million USD | 25.52% |
| 2016 Q1 | 13.04 Million USD | 3.63% |
| 2015 Q4 | 12.58 Million USD | -14.62% |
| 2015 FY | 12.58 Million USD | -6.35% |
| 2015 Q1 | 13.7 Million USD | 1.94% |
| 2015 Q2 | 13.59 Million USD | -0.8% |
| 2015 Q3 | 14.74 Million USD | 8.46% |
| 2014 Q1 | 7.95 Million USD | 11.26% |
| 2014 FY | 13.44 Million USD | 87.93% |
| 2014 Q4 | 13.44 Million USD | 20.6% |
| 2014 Q3 | 11.14 Million USD | 10.34% |
| 2014 Q2 | 10.1 Million USD | 26.94% |
| 2013 Q4 | 7.15 Million USD | 37.86% |
| 2013 FY | 7.15 Million USD | 520.83% |
| 2013 Q1 | 3.11 Million USD | 170.23% |
| 2013 Q2 | 4.31 Million USD | 38.61% |
| 2013 Q3 | 5.18 Million USD | 20.23% |
| 2012 Q1 | - USD | -100.0% |
| 2012 Q2 | - USD | 0.0% |
| 2012 FY | 1.15 Million USD | 196.14% |
| 2012 Q4 | 1.15 Million USD | 4330.77% |
| 2012 Q3 | 26 Thousand USD | 0.0% |
| 2011 Q3 | 3.99 Million USD | 0.0% |
| 2011 Q4 | 389 Thousand USD | -90.26% |
| 2011 FY | 389 Thousand USD | -94.24% |
| 2010 FY | 6.75 Million USD | 187.81% |
| 2010 Q3 | 1.95 Million USD | 0.0% |
| 2010 Q4 | 6.75 Million USD | 246.29% |
| 2009 FY | 2.34 Million USD | -64.16% |
| 2009 Q4 | 2.34 Million USD | 0.0% |
| 2008 FY | 6.54 Million USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -543.779% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -305.787% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | -29.67% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -697.527% |
| bluebird bio, Inc. | 22.91 Million USD | -237.746% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -2643.991% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 79.939% |
| Myriad Genetics, Inc. | 20.1 Million USD | -285.114% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | -102.11% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.07% |
| Waters Corporation | 516.23 Million USD | 85.005% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 98.479% |
| Biogen Inc. | 2.52 Billion USD | 96.937% |
| Nektar Therapeutics | 16.1 Million USD | -380.765% |
| Perrigo Company plc | 1.14 Billion USD | 93.215% |
| Dynavax Technologies Corporation | 53.29 Million USD | -45.258% |
| Illumina, Inc. | 587 Million USD | 86.813% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -646.317% |
| Heron Therapeutics, Inc. | 42.11 Million USD | -83.823% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 93.009% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -603.837% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 97.0% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | -17.959% |
| FibroGen, Inc. | 41.56 Million USD | -86.234% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 92.492% |
| OPKO Health, Inc. | 65.69 Million USD | -17.826% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 13.167% |
| Exelixis, Inc. | 17.32 Million USD | -346.851% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 96.981% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -411.45% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 3267.267% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 89.522% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 28.42 Million USD | -172.324% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 76.024% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -901.397% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | 39.336% |
| Blueprint Medicines Corporation | 21.22 Million USD | -264.736% |
| Insmed Incorporated | 83.24 Million USD | 7.015% |
| TG Therapeutics, Inc. | 39.82 Million USD | -94.38% |
| Incyte Corporation | 62.97 Million USD | -22.924% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 76.465% |